NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
申请人:SCHWINK Lothar
公开号:US20090264403A1
公开(公告)日:2009-10-22
The invention relates to azacyclyl-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the azacyclyl-substituted aryidihydroisoquinolinones of the invention and their derivatives as MCH antagonists.
[DE] SUBSTITUIERTE N-ARYLHETEROZYKLEN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS<br/>[FR] N-ARYLHETEROCYCLES SUBSTITUES, PROCEDE DE PRODUCTION ET UTILISATION DE CES DERNIERS EN TANT QUE MEDICAMENTS
申请人:AVENTIS PHARMA GMBH
公开号:WO2004072025A3
公开(公告)日:2004-12-23
AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
申请人:SANOFI
公开号:EP1987020B1
公开(公告)日:2012-10-03
US8822495B2
申请人:——
公开号:US8822495B2
公开(公告)日:2014-09-02
[EN] AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS<br/>[FR] NOUVELLES ARYLDIHYDROISOQUINOLINONES À SUBSTITUTION AZACYCLYLE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS
申请人:SANOFI AVENTIS
公开号:WO2007093364A1
公开(公告)日:2007-08-23
[EN] The invention relates to azacyclyl-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the azacyclyl-substituted aryldihydroisoquinolinones of the invention and their derivatives as MCH antagonists. [FR] L'invention concerne des aryldihydroisoquinolinones à substitution azacyclyle et leurs dérivés ainsi que leurs sels physiologiquement tolérés et leurs dérivés physiologiquement fonctionnels, leur préparation, des médicaments comprenant au moins une aryldihydroisoquinolinone à substitution azacyclyle de l'invention ou un de ses dérivés, ainsi que l'utilisation des aryldihydroisoquinolinones à substitution azacyclyle de l'invention et de leurs dérivés comme antagonistes de l'hormone de mélanoconcentration (MCH).